The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunityChristina K. Baumgartner, Joshua H. Decker, Prasanthi Geda et al.|Nature|2023Cited by 170
Abstract 606: Targeting the immune checkpoint PTPN2 with ABBV-CLS-484 inflames the tumor microenvironment and unleashes potent CD8+ T cell immunityArvin Iracheta‐Vellve, Robert T. Manguso, Hakimeh Ebrahimi-Nik et al.|Cancer Research|2022Cited by 8
Abstract ND06: ABBV-CLS-484: An active site PTPN2/N1 inhibitor that augments the immune response and sensitizes tumors to immune-mediated killingChristina K. Baumgartner, Philip R. Kym, Marcia N. Paddock et al.|Cancer Research|2022Cited by 7
Quantitative target engagement of RIPK1 in human whole blood via the cellular thermal shift assay for potential pre-clinical and clinical applicationsShitalben Patel, James E. Kath, Marie Karlsson et al.|SLAS DISCOVERY|2023Cited by 1
1365 An active site PTPN2/N1 small molecule inhibitor promotes anti-tumor efficacy by sensitizing tumor cells to inflammatory signals and enhancing immune cell activityKathleen A. McGuire, Philip R. Kym, Christina K. Baumgartner et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1